Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Medication Use Trends in Newly-Diagnosed Diabetes

Diabetes Care; ePub 2017 Nov 6; Montvida, et al

Even in the face of newer treatment options, sulfonylureas remain the most popular second-line anti-diabetes medication in people with newly-diagnosed diabetes, researchers concluded after conducting a study involving >1 million individuals. Participants were between 18 and 80 years of age, had type 2 diabetes, and initiated an anti-diabetes drug. Among the results:

  • Between 2005 to 2016, first-line use of metformin increased from 60% to 77%.
  • It decreased for sulfonylureas from 20% to 8%.
  • During an average follow-up of ~3.5 years after initiating metformin, ~half started a second anti-diabetes drug; the average HbA1c in this group was 8.4%.
  • Among those who started a second drug after first-line metformin, sulfonylurea use decreased from 60% to 46%, yet it remained the most popular second choice.
  • Use increased for insulin from 7% to 17%, and for DPP4 inhibitors from 0.4% to 21%.
  • Intensification rates with insulin and sulfonylureas did not decline over the 10 years analyzed.
Citation:

Montvida O, Shaw J, Atherton J, Stringer F, Paul S. Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes. [Published online ahead of print November 6, 2017]. Diabetes Care. doi:10.2337/dc17-1414.

This Week's Must Reads

Severe Hypoglycemia’s Impact on CVD, Mortality, Diabetes Care; ePub 2017 Nov 10; Lee, et al

Medically Treated Primary Aldosteronism Outcomes, Lancet Diabetes Endocrinol; ePub 2017 Nov 9; Hundemer, et al

Weight Gain’s Impact on CV Outcomes in T1D Studied, Diabetes Care; ePub 2017 Nov 14; Purnell, et al

Cesarean Delivery Odds in Hispanic Women Assessed, Obesity; ePub 2017 Nov 16; Harvey, et al

Competitive Bidding and Diabetes Supplies Access, Diabetes Care; ePub 2017 Nov 17; Puckrein, et al

Must Reads in Diabetes

Severe Hypoglycemia’s Impact on CVD, Mortality, Diabetes Care; ePub 2017 Nov 10; Lee, et al

Weight Gain’s Impact on CV Outcomes in T1D Studied, Diabetes Care; ePub 2017 Nov 14; Purnell, et al

Competitive Bidding and Diabetes Supplies Access, Diabetes Care; ePub 2017 Nov 17; Puckrein, et al

Cochrane on Diet/Exercise Role in Preventing GDM, Cochrane, 2017 Nov 12; Shepherd, Gomersal, et al

Sustainability of Diabetes Prevention Approaches, JAMA Intern Med; ePub 2017 Nov 6; Haw, et al